日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Correction: Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis

更正：新型免疫疗法肝脏安全性的全球评估：系统评价和荟萃分析

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2026.1788767
Ye, Minyan; Dong, Yinuo; Li, Xiaoyun; Zhi, Yang; Lu, Yuping; Tang, Jieting; Zhong, Wei; Lei, Xiaohong; Mao, Yimin; Huang, Sha; Song, Yanyan
免疫/内分泌
发表日期：2026
文献求助 收藏

FGF2 Mediated USP42-PPARγ Axis Activation Ameliorates Liver Oxidative Damage and Promotes Regeneration.

FGF2 介导的 USP42-PPARα 轴激活可改善肝脏氧化损伤并促进再生

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202408724
Yang Nanfei, Tian Qiang, Lei Zhenli, Wang Shuxin, Cheng Nan, Wang Zhen, Jiang Xianqin, Zheng Xuqun, Xu Wenjing, Ye Minyan, Zhao Longwei, Wen Meiyun, Niu Jianlou, Sun Weijian, Shen Pingping, Huang Zhifeng, Li Xiaokun
毒理研究
肝损伤
发表日期：2025
文献求助 收藏

Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis

新型免疫疗法肝脏安全性的全球评估：系统评价和荟萃分析

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2025.1677998
Ye, Minyan; Dong, Yinuo; Li, Xiaoyun; Zhi, Yang; Lu, Yuping; Tang, Jieting; Zhong, Wei; Lei, Xiaohong; Mao, Yimin; Huang, Sha; Song, Yanyan
免疫/内分泌
发表日期：2025
文献求助 收藏

Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence

应对抗体药物偶联物的肝毒性：从机制研究到临床和上市后证据

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2025.1694436
Dong, Yinuo; Zhi, Yang; Li, Xiaoyun; Ma, Mingyang; Ye, Minyan; Huang, Sha; Tang, Jieting; Zhong, Wei; Lei, Xiaohong; Mao, Yimin
毒理研究
发表日期：2025
文献求助 收藏